---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-21-002694"
form_type: "8-K"
ticker: "CMMB"
cik: "0001534248"
company_name: "Chemomab Therapeutics Ltd."
filed_at: "2021-08-13T23:59:59+00:00"
generated_at: "2026-06-29T11:19:48.001094+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Chemomab Q2 net loss $2.8M; cash $67M; Phase 2 trials on track for 2022 data

## Summary
- Net loss $2.8M ($0.01 per share) vs $1.1M loss in Q2 2020; R&D expenses $1.3M (up from $0.8M).
- Cash and equivalents $67M at June 30, 2021, up from $58.2M at March 31; runway to mid 2023.
- CM-101 Phase 2a SPRING (PSC) and SPLASH (liver fibrosis) enrolling; data expected in 1H/2H 2022.
- Expanded partnership with AGC Biologics to manufacture CM-101 for pivotal studies and launch readiness.
- Plan to initiate Phase 2 trial in Systemic Sclerosis in Q1 2022.

## SEC filing metadata
- accession: 0001178913-21-002694
- form_type: 8-K
- ticker: CMMB
- cik: 0001534248
- company_name: Chemomab Therapeutics Ltd.
- filed_at: 2021-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002694/0001178913-21-002694-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534248/000117891321002694/zk2126454.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-21-002694
- JSON: https://secwatch.observer/filing/0001178913-21-002694.json
- Plain text: https://secwatch.observer/filing/0001178913-21-002694.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.